Provided in the present invention is a monoclonal antibody NJ001-1 against human non-small-cell lung carcinoma. The antibody is secreted by the hybridoma cell strain NM001-1 with deposit no. CCTCCNO: C201172, and has specific reactivity against lung adenocarcinoma and squamous carcinoma cell lines. Also provided in the present invention is the use of the above-mentioned antibody in preparing drugs for treating human non-small-cell lung carcinoma.